EUVIMEDEUVIMED entdecken
Crossref

P-glycoprotein-mediated impairment of doxorubicin clearance in inflammatory bowel disorders: Mechanistic insights from rat studies and whole-body physiologically based pharmacokinetic modeling

Mo'tasem M Alsmadi

Drug Metabolism and Disposition · 2026-04 · 54 (4) · 100254

DOI: 10.1016/j.dmd.2026.100254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-04. Verfasst von Mo'tasem M Alsmadi. Beteiligte Einrichtung: Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan; Nanotechnology Institute, J…. Hauptthemen laut MEDLINE: Doxorubicin, Inflammatory Bowel Diseases, ATP Binding Cassette Transporter, Subfamily B, Member 1, Antibiotics, Antineoplastic. Die Arbeit nennt 108 Literaturangaben. Gefördert von: Jordan University of Science and Technology, Jordan University of Science and Technology Deanship of Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin (Dox) cardiotoxicity can worsen due to increased cardiac accumulation. P-glycoprotein downregulation, common in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), may influence Dox pharmacokinetics (PK) and cardiotoxicity, but its impact remains unexplored. This study investigated the mechanistic effects of IBS/IBD on Dox-induced cardiotoxicity. An IBS/IBD rat model assessed Dox PK after intravenous bolus (2.5 mg/kg) and oral (10 mg/kg) dosing. A whole-body physiologically based pharmacokinetic model was developed to predict Dox cardiac concentration in rats and humans. In rats, intravenous Dox clearance decreased by 70% in IBS, tripling plasma concentration, while IBD had a milder effect. Oral Dox bioavailability dropped by 85% in IBS and 50% in IBD, likely due to delayed gastric emptying. The whole-body physiologically based pharmacokinetic model predicted elevated cardiac interstitial fluid (ISFHeart) Dox concentrations surpassing cardiotoxicity thresholds in IBS/IBD rats. Human simulations showed 4- to 5-fold higher plasma concentration in IBS/IBD patients receiving intravenous Dox (60 mg/m2), nearing toxic levels. IBS/IBD prolongs Dox ISFHeart retention, increasing apoptosis-mediated cardiotoxicity risk, especially with bolus dosing. These findings highlight the critical impact of IBS/IBD on Dox PK and toxicity, advocating for personalized chemotherapy approaches. SIGNIFICANCE STATEMENT: This study shows that irritable bowel syndrome and inflammatory bowel disease alter doxorubicin disposition via impaired P-glycoprotein activity, reducing clearance, elevating systemic exposure, and increasing cardiac concentration of doxorubicin. Using rat models with whole-body physiologically based pharmacokinetic simulations, this study reveals how transporter dysfunction and gastrointestinal changes influence pharmacokinetics and toxicity. Findings extend knowledge beyond dose-dependent cardiotoxicity, highlighting comorbidities in drug disposition and underscoring disease-drug interactions for precision dosing in cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinInflammatory Bowel DiseasesATP Binding Cassette Transporter, Subfamily B, Member 1Antibiotics, AntineoplasticAnimalsRatsHumansMaleModels, BiologicalRats, Sprague-DawleyCardiotoxicityDisease Models, AnimalAdministration, OralBiological AvailabilityMetabolic Clearance Rate

Stichwörter der Autor:innen

Delayed gastric emptyingDoxorubicin cardiotoxicityInflammatory bowel diseaseIrritable bowel syndromeMechanistic whole body physiologically based pharmacokinetic modelingP-glycoprotein

Substanzen

DoxorubicinATP Binding Cassette Transporter, Subfamily B, Member 1Antibiotics, Antineoplastic

Autor:innen und Institutionen

  • Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan; Nanotechnology Institute, Jordan University of Science and Technology, Irbid, Jordan. Electronic…

Förderung

  • Jordan University of Science and Technology
  • Jordan University of Science and Technology Deanship of Research

Zitieren

APA

Alsmadi, M. M. (2026). P-glycoprotein-mediated impairment of doxorubicin clearance in inflammatory bowel disorders: Mechanistic insights from rat studies and whole-body physiologically based pharmacokinetic modeling. Drug Metabolism and Disposition, 54(4), 100254. https://doi.org/10.1016/j.dmd.2026.100254

Vancouver

Alsmadi MM. P-glycoprotein-mediated impairment of doxorubicin clearance in inflammatory bowel disorders: Mechanistic insights from rat studies and whole-body physiologically based pharmacokinetic modeling. Drug Metabolism and Disposition. 2026;54(4):100254. doi:10.1016/j.dmd.2026.100254

BibTeX
@article{Alsmadi2026,
  author = {Alsmadi, Mo'tasem M},
  title = {P-glycoprotein-mediated impairment of doxorubicin clearance in inflammatory bowel disorders: Mechanistic insights from rat studies and whole-body physiologically based pharmacokinetic modeling},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {4},
  pages = {100254},
  doi = {10.1016/j.dmd.2026.100254}
}
Kostenlos starten →